Canadian Cancer Trials Group Bulletins

General


Recent Publication

Final results of Canadian Cancer Trials Group PA.2 (ESPAC-3) -- Phase III Adjuvant Trial In Pancreatic Cancer Comparing (1) 5FU And D-L Folinic Acid Vs (2) Gemcitabine Vs (3) No Adjuvant Treatment -- were recently published in the Journal of the American Medical Association (JAMA).

The results of this trial show that the use of gemcitabine, a drug that can be effective in treating advanced and resected pancreatic cancer, did not result in improved overall survival after pancreatic cancer resection (surgical removal) compared to patients who received fluorouracil and folinic acid, another treatment regimen that has shown effectiveness.

The trial has, therefore, defined the world-wide standard of care for the treatment of patients after surgical resection of a cancer of the pancreas. It was a cooperative venture of European and Canadian investigators with the Canadian participation coordinated by the Canadian Cancer Trials Group. "This was an important study for the Canadian surgeons and medical oncologists who treat pancreatic cancer," said Dr. Malcolm Moore and Dr. Steven Gallinger of Princess Margaret Hospital, the study chairs. "It demonstrated that we can work together to answer important questions and is an important foundation for future Canadian clinical research in pancreatic cancer."

The publication is available online at http://jama.ama-assn.org/cgi/reprint/304/10/1073.